Prellis Biologics Overview
- Year Founded
-
2016
- Status
-
Private
- Employees
-
60
- Latest Deal Type
-
Series C1
- Investors
-
15
Prellis Biologics General Information
Description
Developer of a bioprinting technology designed to recreate and engineer human tissues in vitro. The company's technology precisely reproduces the human immune response through the creation of lymph node organoids and can exploit fully human immune responses for a variety of applications, including antibody discovery, immunogenicity assessment, and tumor-immune models, improving patients' lives by addressing challenges commonly faced in early-stage drug discovery and translational pharmacology.
Contact Information
Website
www.prellisbio.comCorporate Office
- 999 Anthony Street
- Berkeley, CA 94710
- United States
Corporate Office
- 999 Anthony Street
- Berkeley, CA 94710
- United States
Prellis Biologics Timeline
Prellis Biologics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 9. Later Stage VC (Series C1) | 27-May-2026 | Completed | Generating Revenue | |||
| 8. Later Stage VC (Series C) | 28-Nov-2023 | Completed | Generating Revenue | |||
| 7. Later Stage VC (Series C) | 10-Aug-2022 | Completed | Generating Revenue | |||
| 6. Later Stage VC (Series B) | 14-Jul-2021 | Completed | Generating Revenue | |||
| 5. Secondary Transaction - Private | 03-May-2021 | Completed | Generating Revenue | |||
| 4. Early Stage VC (Series A) | 21-Mar-2019 | Completed | Startup | |||
| 3. Seed Round | 19-Apr-2018 | Completed | Startup | |||
| 2. Accelerator/Incubator | 22-Jun-2017 | $250K | $250K | Completed | Startup | |
| 1. Accelerator/Incubator | Completed | Startup |
Prellis Biologics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series C | ||||||||
| Series B Prime | ||||||||
| Series B | ||||||||
| Series A | ||||||||
| Seed Prime | 1,191,043 | $0.000100 | 8% | $0.21 | $0.21 | 1x | $0.21 | 0.87% |
| Seed | 6,634,718 | $0.000100 | 8% | $0.27 | $0.27 | 1x | $0.27 | 4.84% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Prellis Biologics Comparisons
Industry
Financing
Details
Prellis Biologics Competitors (13)
One of Prellis Biologics’s 13 competitors is Aspect Biosystems, a Venture Capital-Backed company based in Vancouver, Canada.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Aspect Biosystems | Venture Capital-Backed | Vancouver, Canada | ||||
| TransGenex Nanobiotech | Formerly Accelerator/Incubator backed | Tampa, FL | ||||
| PrintBio | Venture Capital-Backed | Long Island City, NY | ||||
| Frontier Bio | Venture Capital-Backed | Hayward, CA | ||||
| InSphero | Private Equity-Backed | Schlieren, Switzerland |
Prellis Biologics Patents
Prellis Biologics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026035990-A2 | Methods of generating antibodies that are human from the start | Pending | 09-Aug-2024 | ||
| WO-2026035990-A3 | Methods of generating antibodies that are human from the start | Pending | 09-Aug-2024 | ||
| US-20250353252-A1 | Methods and systems for three-dimensional printing | Pending | 01-Jun-2022 | ||
| WO-2023114785-A2 | Three-dimensional bio-engineered lymphoid organs and organoids for cell-based therapies | Inactive | 14-Dec-2021 | ||
| WO-2023114785-A3 | Three-dimensional bio-engineered lymphoid organs and organoids for cell-based therapies | Inactive | 14-Dec-2021 | B33Y80/00 |
Prellis Biologics Signals
Prellis Biologics Investors (15)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Open Field Capital | Venture Capital | Minority | ||
| Avidity Partners | Asset Manager | Minority | ||
| Black Diamond Ventures | Venture Capital | Minority | ||
| Celesta Capital | Venture Capital | Minority | ||
| Future Ventures (San Francisco) | Venture Capital | Minority |
Prellis Biologics FAQs
-
When was Prellis Biologics founded?
Prellis Biologics was founded in 2016.
-
Where is Prellis Biologics headquartered?
Prellis Biologics is headquartered in Berkeley, CA.
-
What is the size of Prellis Biologics?
Prellis Biologics has 60 total employees.
-
What industry is Prellis Biologics in?
Prellis Biologics’s primary industry is Other Healthcare Technology Systems.
-
Is Prellis Biologics a private or public company?
Prellis Biologics is a Private company.
-
What is Prellis Biologics’s current revenue?
The current revenue for Prellis Biologics is .
-
How much funding has Prellis Biologics raised over time?
Prellis Biologics has raised $70.2M.
-
Who are Prellis Biologics’s investors?
Open Field Capital, Avidity Partners, Black Diamond Ventures, Celesta Capital, and Future Ventures (San Francisco) are 5 of 15 investors who have invested in Prellis Biologics.
-
Who are Prellis Biologics’s competitors?
Aspect Biosystems, TransGenex Nanobiotech, PrintBio, Frontier Bio, and InSphero are some of the 13 competitors of Prellis Biologics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process